Spots Global Cancer Trial Database for Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)
Official Title: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)
Study ID: NCT04736485
Interventions
Study Description
Brief Summary: Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CHU Besançon, Besançon, , France
Centre François Baclesse, Caen, , France
Centre Georges Francois Leclerc, Dijon, , France
Chru Lille, Lille, , France
APHM Marseille, Marseille, , France
Institut Régional Cancer, Montpellier, , France
APHP St Louis, Paris, , France
Institut Mutualiste Montsouris, Paris, , France
CHU Poitiers, Poitiers, , France
CHU Robert Debré, Reims, , France
Centre Eugène Marquis, Rennes, , France
ICO St Herblain, Saint-Herblain, , France
CH St Malo, Saint-Malo, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
